《新股消息》百威亚太(01876.HK)明起招股入场费4,747.36元
百威亚太(01876.HK)明起至7月11日招股,每股招股价介乎40-47元,每手100股计,入场费4,747.36元。
是次共发行16.27亿股,其中5%在港作公开发售,摩根大通和摩根士丹利为联席保荐人。股份会於7月19日上市。
以中位数计,集资净额为692.5亿元,会即时用於偿还应付百威集团附属公司的贷款以完成重组,包括全数偿还韩国债务应收贷款项下,对Mexbrew Investment SARL的债务;及偿还股东贷款项下对AB InBev Investment的部份债务。
若超额配股权得以行驶,将偿还对APAC HoldCo2 的债务;若未能行使,则会向其发行相同数目股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.